Research
Hormonal
Inhibitors of histone deacetylases (HDACs) can restore lost memories and reverse cognitive phenotypes in mouse models of Alzheimer's disease by targeting locus-specific chromatin alterations.
Current research indicates that HDAC inhibitors show promise in restoring memory in animal models of Alzheimer's. However, these are experimental therapies not yet available for human use. Focus on proven lifestyle interventions like exercise and cognitive engagement to support brain health.
LimitedSupportsLOW confidence
Provocatively, mouse models for neurodegeneration can recover lost memories when treated with inhibitors of histone deacetylases (27,28). hence, these inhibitors are potential epigenetic therapies in the treatment of AD and may even be restorative for lost memories.
Why this rating
Evidence is derived from mouse models of neurodegeneration, not human clinical trials.
Source
Epigenetics of Aging and Aging-related Disease
Anne Brunet et al. · The Journals of Gerontology Series A · 2014
DOI 10.1093/gerona/glu042
narrative_reviewCited 264×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary restriction and exercise delay aging by enhancing Sirtuin activity, which deacetylates histones and substrates to protect against age-related diseases and extend healthspan.Moderate
- Cellular reprogramming to induced pluripotent stem cells (iPSCs) can model progeroid syndromes and reveal epigenetic defects associated with premature aging, offering a platform for screening epigenetic therapeutics.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →